Skip to main content
Clinical Trials/CTRI/2012/08/002897
CTRI/2012/08/002897
Completed
未知

A Prospective, Open-labeled, Clinical Study to evaluate the efficacy and safety of Depiklen for the treatment of hyper-pigmentation disorders in adults

Sante Mernaud Pharmaceuticals Pvt Ltd0 sites24 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Sante Mernaud Pharmaceuticals Pvt Ltd
Enrollment
24
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
March 29, 2013
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Sante Mernaud Pharmaceuticals Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • Males and females of age group 18\-60 years
  • Subjects who are willing to give written informed consent.
  • Subjects with Fitzpatrick Skin types II to IV
  • Subjects with hyper pigmentation disorders such as Melasma and lentigo (mild to moderate).
  • Patient is willing and able to comply with all trial requirements

Exclusion Criteria

  • Having major treatment, including topical hydroquinone or tretinoin, cryotherapy, electro\-surgery, trichloroacetic acid application, laser or intense pulsed light, in the 3 months before the beginning of the study
  • Past history of allergy to whitening cosmetic products
  • Past history of atopic dermatitis
  • Habit of going to the tanning salon or frequent sun exposure longer than 4 hours per day
  • Present history of mental diseases
  • Previous participation in a clinical trial within 6 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials